The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: Sweden
ID NLM: 8709065

Informations de publication

Date de publication:
30 Jun 2024
Historique:
received: 26 10 2023
accepted: 24 04 2024
medline: 1 7 2024
pubmed: 1 7 2024
entrez: 1 7 2024
Statut: epublish

Résumé

In evaluating second primary cancers (SPCs) following External Beam Radiotherapy (EBRT), the role of lifestyle factors is frequently not considered due to data limitations. We investigated the association between smoking, comorbidities, and SPC risks within EBRT-treated patients for localized prostate cancer (PCa). The study included 1,883 PCa survivors aged 50-79, treated between 2006 and 2013, with intensity-modulated radiotherapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT). Clinical data were combined with SPC and survival data from the Netherlands Cancer Registry with a 12-month latency period. Standardized Incidence Ratios (SIRs) were calculated comparing the EBRT cohort with the general Dutch population. To explore the effect of patient and treatment characteristics on SPCs we conducted a Cox regression analysis. Lastly, we estimated cumulative incidences of developing solid SPC, pelvis SPC, and non-pelvis SPC using a competing risk analysis. Significantly increased SIRs were observed for all SPC (SIR = 1.21, 95% confidence interval [CI]: 1.08-1.34), pelvis SPC (SIR = 1.46, 95% CI: 1.18-1.78), and non-pelvis SPC (SIR = 1.18, 95% CI [1.04-1.34]). Smoking status was significantly associated with pelvic and non-pelvic SPCs. Charlson comorbidity index (CCI) ≥ 1 (Hazard Ratio [HR] = 1.45, 95% CI: 1.10-1.91), cardiovascular disease (HR = 1.41, 95% CI: 1.05-1.88), and chronic obstructive pulmonary disease (COPD) (HR = 1.91, 95% CI: 1.30-2.79) were significantly associated with non-pelvis SPC. The proportion of active smoking numbers in the cohort was similar to the general population. We conclude that the presence of comorbidities in the EBRT population might be a relevant factor in observed excess non-pelvis SPC risk, but not for excess pelvis SPC risk.

Identifiants

pubmed: 38946286
doi: 10.2340/1651-226X.2024.24334
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

511-517

Auteurs

Marie-Christina Jahreiß (MC)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Luca Incrocci (L)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Katja K H Aben (KKH)

Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; Deaprtment for Health Evidence, Radboudumc, Nijmegen, The Netherlands.

Kim C De Vries (KC)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Mischa Hoogeman (M)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Maartje J Hooning (MJ)

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Wilma D Heemsberge (WD)

Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. w.heemsbergen@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH